Pharmaceutical Investing EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone
